Related Experiment Videos
Lipoprotein lipase activator NO-1886
Weidong Yin1, Kazuhiko Tsutsumi
1Department of Biochemistry and Molecular Biology, Medical School, Nanhua University, Hengyang 421001, China. wdy20012001@yahoo.com
Cardiovascular Drug Reviews
|July 9, 2003
Summary
Elevating lipoprotein lipase (LPL) activity with NO-1886 reduces triglycerides and increases HDL cholesterol. This shift in lipid profiles protects against atherosclerosis development, offering potential therapeutic benefits.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Science
Background:
- Lipoprotein lipase (LPL) activity is crucial for lipid metabolism.
- Decreased LPL activity correlates with increased triglycerides and decreased HDL cholesterol, risk factors for cardiovascular disease.
Purpose of the Study:
- To investigate if enhancing LPL activity can reduce plasma triglycerides (TG) and increase high-density lipoprotein cholesterol (HDL-C).
- To determine if LPL activation protects against atherosclerosis development.
Main Methods:
- Otsuka Pharmaceutical Factory synthesized the LPL activator NO-1886.
- NO-1886 administration to rats and rabbits.
- Assessment of LPL activity, mRNA levels, plasma lipid profiles, and atherosclerotic lesion development.
Main Results:
- NO-1886 increased LPL mRNA and activity in multiple tissues, elevating postheparin plasma LPL activity and mass.
- NO-1886 decreased plasma TG and increased plasma HDL-C.
- Long-term NO-1886 administration inhibited atherosclerotic lesion development in coronary arteries and aortas.
Conclusions:
- Elevating LPL activity favorably alters lipid profiles, shifting from atherogenic to antiatherogenic.
- NO-1886 demonstrates potential for treating hypertriglyceridemia, hypo-HDL cholesterolemia, and preventing atherosclerosis.